Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia

Br J Haematol. 2015 Sep;170(5):734-6. doi: 10.1111/bjh.13328. Epub 2015 Feb 25.

Authors

Sudhir Manda¹, Nancy Dunbar¹, Cynthia R Marx-Wood¹, Alexey V Danilov^{2

3}

Affiliations

¹ Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
² Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. danilov@ohsu.edu.
³ Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA. danilov@ohsu.edu.

PMID: 25716177
DOI: 10.1111/bjh.13328

No abstract available

Keywords: autoimmune haemolytic anaemia; chronic lymphocytic leukaemia; ibrutinib.

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Aged
Anemia, Hemolytic, Autoimmune / diagnosis
Anemia, Hemolytic, Autoimmune / drug therapy*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Male
Piperidines
Pyrazoles / administration & dosage*
Pyrimidines / administration & dosage*

Substances

Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Adenine